Comparar compuestos

Start

2 mg

Range

2–5 mg per week

Frequency

2× weekly (loading), then weekly

Cycle

4–6 week loading, then maintenance

Vials

5 / 10 mg

Ajuste gradual

1. Weeks 1–4: 2–2.5 mg, twice weekly
2. Weeks 5+: 2 mg, once weekly

TB-500 has been analytically identified as the acetylated thymosin β4 residues 17–23 fragment, Ac-LKKTETQ; some suppliers also use that name for full-length 43-amino-acid thymosin β4. These are not interchangeable. The wound-repair findings below concern full-length thymosin β4, which binds G-actin and participates in cell migration; confirm the sequence of any supplier-labeled product.

• In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 vs saline.
• In the same full-length thymosin β4 study, treated wounds contracted at least 11% more by day 7, with more collagen deposition and new blood vessels.
• Full-length thymosin β4 increased keratinocyte migration 2–3-fold in cell-culture assays; this is not evidence for an arbitrary TB-500-labeled vial.

• Most evidence is on full-length thymosin β4; data on the TB-500 fragment itself is limited.
• Not approved for human use; listed as prohibited by the World Anti-Doping Agency.

3 referencias · ver